cyrilzakka/clinical-trials huggingface dataset:
Dexmedetomidine and Myocardial Protection

Dexmedetomidine, an alpha-2 agonist, is a sedative that is widely used in various clinical settings because, compared to benzodiazepines, it preserves respiratory function better and its duration of action is short.

Recent experimental studies showed a possibility that dexmedetomidine may have an organoprotective effect from ischemic-reperfusion injury by reducing inflammatory response. Besides, dexmedetomidine is known to be related with attenuated sympathetic tone and improved microcirculation.

Taken together, it is plausible that dexmedetomidine exerts cardioprotection in patients undergoing cardiac surgery with cardiopulmonary bypass and aortic cross-clamp.

The aim of this trial is to test the effect of dexmedetomidine on postoperative cardiac troponin I measurements in patients undergoing cardiac surgery.


Eligibility Criteria:
Inclusion Criteria:

* cardiac surgery utilizing cardiopulmonary bypass and aortic cross-clamp

Exclusion Criteria:

* Coronary artery bypass grafting
* Concomitant cryo-Maze procedure
* Myectomy
* Heart transplantation
* Concomitant major non-cardiac surgery
* Isolated complicated congenital heart surgery
* descending thoracic aorta surgery with partial cardiopulmonary bypass
* Emergency surgery
* Minimally invasive or robot-assisted surgery
* Estimated GFR \<30 ml/min/1.73 m2
* Documented end-stage renal disease
* Preoperative renal replacement therapy
* Preoperative history of percutaneous coronary intervention within 6 month before surgery
* Acute coronary syndrome within 4 weeks before surgery
* Preoperative mechanical circulatory support devices
Investigation of the Effect of Motor Imagery Training in Individuals with Cervical Discogenic Pain

In this study, motor control exercises including cervical region, upper extremity and scapular region muscles will be applied routinely in individuals with chronic neck pain. The application will been investigating, called motor imagery training, will been carried out together with motor control exercises.

This training is a mental exercise method based on imagining exercises that are performed actively without any interventional application inside or outside the body, in a comfortable environment and without fatigue. It is thought that motor imagery training applied together with motor control exercises will contribute to the management of chronic neck pain due to cervical disc herniation and symptoms related to pain.

All individuals with cervical discogenic pain who met the inclusion criteria were assigned to '1. Group' and '2. It will be divided into two groups. It is planned to include approximately 20 individuals with cervical discogenic pain in each group. The sample size of the study will be determined by the power analysis to be made as a result of the pilot study to be carried out on 10 patients with the support of Biostatistics USA.

Group 1: (estimated) 20 Individuals with Cervical Discogenic Pain Group 2: (estimated) 20 Individuals with Cervical Discogenic Pain

Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18 and 65,
* Having a diagnosis of cervical disc herniation based on MRI findings, clinical, and physical examination,
* Experiencing neck pain for 3 months or longer,
* Having a resting pain intensity rated 3-7 (moderate severity) on the "Visual Analog Scale" for pain assessment (36),
* Classifying neck pain according to the 'Neck Pain Task Force' clinical classification system as Grade 3 (neck pain with accompanying neurological symptoms) or above,
* Having a Mini-Mental Test score of 24 or higher for the evaluation of cognitive functions.

Exclusion Criteria:

* Having a history of spinal tumor, spinal deformities, congenital malformation, or head trauma,
* Undergoing cervical spine surgery in the last 6 months,
* Having a presence of systemic, cardiorespiratory, central nervous system, or rheumatic diseases, any musculoskeletal or craniocervical disorders, or a history of headache.
Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

QT/QTc interval prolongation is investigated during the first two weeks of subject participation in the parallel phase 3 study. The pre-cordial leads and lead II will be utilized to determine QT/QTc prolongation. Descriptive information is provided on changes in T and U wave morphologies. The percentage of subjects in each therapy group who have worsening of the T and U wave morphology is documented. Discrete U waves are excluded from the QT/QTc interval measurement. Except for the pre-therapy ECGs, all ECGs are performed during one ANP therapy infusion daily, that being an afternoon infusion to account for diurnal variation in the QT/QTc interval. The study subject is at rest in the supine position for 30 minutes prior to the ECG study. The baseline QTc is derived from 3 ECGs taken on day 1 during the hour preceding the first Antineoplaston therapy infusion or the first radiation session.

Eligibility Criteria:
Inclusion Criteria:

* Enrolled in BRI-BT-52

Exclusion Criteria:

* Not enrolled in BRI-BT-52
Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia

This study evaluates the effects of Multimodal Cognitive Enhancement Therapy (MCET) for people with mild cognitive impairment and early stage dementia by a randomized, controlled (mock-therapy), double-blind, cross-over trial

Multimodal Cognitive Enhancement Therapy (MCET) was developed for cognitive rehabilitation of mild cognitive impairment or ealy dementia. MCET consists of cognitive training, cognitive stimulation, reality orientation, physical therapy, reminiscence therapy and music therapy that obtained 'A' grade of recommendation by SIGN(Scottish Intercollegiate Guidelines Network) for their efficacy (one of the followings: global cognition/specific cognitive domain/mood/activities of daily living/behavioral and psychological symptoms/quality of life) based on the systematic review and meta-analysis performed by our research team.

This study investigated the efficacy of MCET compared with mock-therapy that consisted of random activities that were not based on clinical evidences (e.g., watching TV, conversation etc.).

Eligibility Criteria:
Inclusion Criteria:

* Aged 55-90
* Diagnosed to dementia by the Diagnostic and Statistical Manual, fourth edition (DSM-IV) or to mild cognitive impairment by International Working Group on Mild Cognitive Impairment
* Clinical Dementia Rating (CDR) of 0 or 0.5 for mild cognitive impairment, 0.5 or 1 for early dementia

Exclusion Criteria:

* Evidence of current delirium, confusion
* Any acute neurological conditions (infectious or inflammatory disorders such as viral, fungal or syphilis) or acute medical conditions
* Current major psychiatric disorder by DSM-IV such as major depressive episode or manic or psychotic episode
Spinal Cord Neuromodulation for Spinal Cord Injury

This study is designed to assess the strategy of using spinal cord stimulation to improve the ability to move in spinal cord injured humans.

An epidural stimulation device will be tested to determine if motor function can be improved.

Eligibility Criteria:
Inclusion Criteria:

1. Stable medical condition without cardiopulmonary disease or dysautonomia that would contraindicate hand/arm movement
2. No severe cardiopulmonary diseases such as severe bradycardia, severe autonomic dysreflexia, and/or Chronic Obstructive Pulmonary Disease.
3. No painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore, or infection that might interfere with upper extremity training
4. No clinically significant depression or ongoing drug abuse
5. No current anti-spasticity medication regimen
6. Non-progressive SCI above C5
7. Must not have received botox injections in the prior six months
8. Be unable to grip or move independently
9. Be at least one-year post injury
10. Must be at least 18 years of age
11. Segmental reflexes remain functional below the lesion
12. Female subjects of child-bearing potential must not be pregnant and must be using a medically acceptable method of contraception
13. No current implant(s) of neurostimulators, cardiac pacemakers, defibrillators, shunts, stents, or aneurysm clips, and must have no future exposure to diathermy following implantation
14. No coagulopathy, cardiac risk factors, or other significant medical risk factors for surgery
15. Must not be involved in another clinical trial
16. Must not have disorders or conditions that would require MRI monitoring

Exclusion Criteria:

None as long as inclusion criteria are met.
Effect Of Cryolipolysis On Visceral Adiposity Index In Polycystic Ovarian Syndrome Patients

this study will be carried to investigate the effect of cryolipolysis on visceral adiposity index in pco women randomized controlled trial

This study will be carried out on sixty females with polycystic ovarian syndrome (PCOS) who were selected from the Outpatient Clinic of Gynecology at Qasr Al Aini University Hospital. Their age ranged from 17-28 years, body mass index was 25-30 Kg/m2. They experienced hyperandrogenism, hyperinsulinemia and amenorrhea not less than 6 months.

PCOS females will be randomly assigned into two equal groups: group (A) (control group) consisted of 30 women who received low caloric diet (1200 Cal/day) and group (B) (study group) consisted of 30 women who received the same diet regime and cryolipolysis

Eligibility Criteria:
Inclusion Criteria:

* age ranges from 20-28 years, body mass index ranges 25-30 Kg/m2. They have pco syndrome .

Exclusion Criteria:

* Diabetic patients.
* Women with BMI\>30
* Women having circulatory dysfunction.
* Women with respiratory or cardiac disease
* liver disease.
* Skin disease .
* Previous abdominal or uterine surgery
* Physical impairment
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.

Arm A: HER2 gene amplification and disease progression following at least 6 weeks of standard doses of Herceptin; Arm B: HER2 gene amplification and no prior Herceptin or HER2-targeted treatment.

Eligibility Criteria:
Inclusion Criteria:

* Pathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IV
* Progression following at least 6 weeks of standard doses of Herceptin (Arm A only)
* Over-expression of HER2
* Tumor tissue available and adequate for analysis at screening
* At least one measurable lesion

Exclusion Criteria:

* Prior treatment with Herceptin (Arm B only)
* More than 4 prior cytotoxic chemotherapy regimens
* Subjects with bone or skin as the only site of measurable disease
* Inadequate cardiac function
* Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within 1 week of treatment day 1
* Active central nervous system metastases
* Pregnant or breastfeeding women
* Inability to swallow the HKI-272 capsules
Requests for Euthanasia and Assisted Suicide in Establishment of Accommodation for Dependent Old Persons.

The main aim of this project is to analyze and understand the meaning of explicit requests to hasten death (euthanasia and assisted suicide) from older people living in an Establishment of accommodation for dependent old persons.

This involves conducting interviews with patients, carers to whom the request has been expressed and a relative chosen by the patient. This study aims to describe the request over time. This will be done through two series of interviews, one as soon as it is first expressed, then one week later.


Eligibility Criteria:
Inclusion Criteria:

* They live in an establishment of accommodation for dependent old persons
* They have to be ill.
* They have request for euthanasie or assisted suicide
* They are in capacity to meet researchers for interview,
* They aggreed to make an individual interview
* They are covered by the French social security system

Exclusion Criteria:

* They have neurocognitives disorders that can't allow an individual interview
* They did not express themselves a request for euthanasia ou assisted suicide
* They disagreed to participate
Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia

The aim of the study is to investigate the efficacy of pulmonary rehabilitation (PR) program to patients with Sars-CoV-2 pneumonia in the post-acute period on pulmonary functions, exercise capacity and anxiety level.

100 patients diagnosed with Sars-CoV-2 pneumonia will be enrolled in this prospective, interventional study according to inclusion/exclusion criteria. Patients will be evaluated and a personalized PR program will be organized before hospital discharge. After discharge, the pulmonary rehabilitation program will continue in telerehabilitation.

In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive exercise videos for these 3 days.

Patients will be followed for 4 weeks and will be called for final evaluation


Eligibility Criteria:
Inclusion Criteria:

* Pneumonia without having severe findings or a need for oxygen support therapy (mild pneumonia) accompanying special conditions (chronic lung / heart disease / diabetes / hypertension / neuromuscular disease history / elderly / immobility etc.)
* Severe pneumonia (A suspicion of fever or respiratory tract infection and having one accompanying finding: respiration rate \>30/min; severe respiratory distress; or SpO2 ≤93% in ambient air.) cases after they get clinically stable (decreased fever, reduced dyspnea, respiratory rate 90%)
* At least 7 days since the diagnosis of SARS-CoV-2 in order to reduce the viral load and the risk of transmission
* Being able to make video calls for telerehabilitation

Exclusion Criteria:

* Serious cardiovascular, cerebrovascular, neuromuscular and other systemic diseases that affect physical activity
* Psychiatric illness and cognitive deficit that will affect patient's exercise cooperation
* Pregnancy
* The deterioration in the general condition of the patient, worsening of the lung findings
* Acute respiratory distress syndrome
Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy

This study aims to verify the impact of four speech therapy sessions on the Quality of Life of patients treated for malignant tongue and/or jaw cancer, using as measure specific questionnaires of speech and swallowing.

The hypothesis is that after treatment with exercises and speech therapy guidance, patients will present better indicators on Quality of Life related to speech and swallowing.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 Years
* Tongue and/or Jaw Neoplasm
* Submitted to surgical treatment

Exclusion Criteria:

* Under 18 Years
* Cognitive impairment or deficits in language comprehension
* Previous speech therapy intervention
* Recurrence or active disease
* Death during the intervention
Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring.

Medication non-adherence is an economic problem and a major public health challenge. Factors influencing medication adherence can be modelled according to five dimensions: disease, medication, patient and its close relatives, demographic and socioeconomic factors and health care system. A tool is needed to qualify medication adherence in order to adapt tailored support for individual patients to promote and optimize adherence to therapy.

The objective of this work is to present the preliminary results of QUILAM project which is divided into 3 phases: 1. Development of a tool to assess barriers to medication adherence in chronic patient (COPD, Heart failure, Type 2 diabetes) ; 2. Validation of the instrument (especially against clinical criteria) ; 3. Evaluation of the sensitivity of the tool during educational interventions.


Eligibility Criteria:
Inclusion Criteria:

* Patient with at least one of the following pathologies: diabetes type II, COPD, heart failure
* person available for a follow-up of 1 year
* Affiliated to the social security or recipient of such a regime

Exclusion Criteria:

* Persons referred to in articles L1121-5 and L1121-8 in the french public health code
* Patient who do not speak french
Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming

The purpose of this clinical trial is to determine whether periodic therapy programming reports illustrating physician usage of shock reduction programming can increase utilization of recommended programming guidelines for defibrillators.

Shocks delivered to patients by defibrillators, while life-saving, can create anxiety, pain and decrease quality of life. Previous studies have shown that device programming and features can safely reduce the number of shocks patients receive. This study will explore the extent to which physicians use these programming and features. It will determine whether repeat and frequent awareness to how they program their own subjects and the programming trends of all enrolled subjects will change their programming patterns. This will be accomplished by understanding physicians' device programming behaviors and providing reports as a tool to help physicians manage their subjects and provide shock reduction programming recommended by previous publications.

Eligibility Criteria:
Inclusion Criteria:

* Subject (or subject's legally authorized representative) is willing and able to sign and date the Patient Consent Form (PCF) and authorization for access to and use of health information, if applicable
* Subject has been implanted with a Medtronic market released ICD or CRT-D device (US/Canada - Concerto®/Virtuoso® or newer model; AsiaPacific, Israel, Latin America - EnTrust™, InSync Sentry®, or Concerto®/Virtuoso® or newer model) within the past 30 days
* Subject has commercially released RA (if applicable), RV, and LV (if applicable) leads

Exclusion Criteria:

* Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the Medtronic Clinical Trial Leader
Studies of Neurological Paraneoplastic Syndromes

This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.

Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:

* analyzing for autoantibodies in serum and cerebral spinal fluid
* analyzing for antigen specificity and for antigens in cancer tissue
* comparing PND autoantibodies with those in cancer patients but no PND
* comparing PND autoantibodies with those in PND patients but no cancer
* studying the immune performance of patients with PNDs

As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.

Eligibility Criteria:
Inclusion Criteria:

* All adults are potentially eligible.

Exclusion Criteria:

* None.
Green Light Therapy As a Non-Pharmacologic Intervention to Decrease Anxiety in Pregnant Women With Opioid Use Disorder

This is a clinical trial evaluating anxiety reduction for women with opioid use disorder affecting pregnancy. It is well documented that anxiety increases as pregnancy progresses. The investigators hypothesize that women who undergo green light therapy (experimental arm) will have a smaller increase in anxiety scores compared to the women who undergo white light therapy (control arm).

The investigators will also look at how much opiate replacement therapy increases women require during the study period, and how much opiate they require during admission for delivery. The investigators think this a is a low risk intervention in a pregnant population that has higher levels of anxiety when compared to the general population. The investigators believe based on animal studies that this could be effective, and change the way providers treat and support individuals with substance use disorder.

The opioid epidemic has negatively impacted our society at many levels. Finding non-pharmacologic ways to support patients while in recovery/sustained sobriety that are simple and low cost would be a step forward in providing compassionate and comprehensive treatment to individuals affected by Opioid Use Disorder.

At time of enrollment, participants will be administered a States-Traits Anxiety Inventory (STAI) questionnaire, undergo screening for ACE score (adverse childhood experiences), and will be asked about basic demographic data. After they complete the initial surveys, the patient will be assigned to either the control group or the experimental group. They will be sent home with the light, along with instructions to use their light every night for 1-2 hours as ambient lighting. The investigators hope to enroll a maximum of 26 patients in this study with 1:1 randomization (13 control, 13 experiment).

At approximately halfway through the intervention, the PI will call the patient and ask how often she has been using the light, how long she uses the light for every night, and whether she has noticed any effects (either positive or negative).

At the prenatal visit around 36 weeks gestation or at time of delivery, whichever is sooner, patients will be asked by the PI to turn in their light and also fill out the STAI once again.

After delivery, the PI will review the medical record and record any change in opioid replacement therapy during pregnancy as well as the total dose of opiate required during the inpatient admission for delivery.

The investigators hope to enroll a maximum of 26 patients in this study with 1:1 randomization (13 control, 13 experiment)

Eligibility Criteria:
Inclusion Criteria:

Pregnant women between 20 - 32 weeks gestation with a diagnosis of opiate use disorder receiving care through Banner University Medical Center North Mothers Over Medicine (MOMs) Clinic, a high-risk pregnancy clinic for women with substance use disorder complicating pregnancy

Exclusion Criteria:

1. Inability to speak or understand English
2. Incarcerated individuals
3. Age \<18 yo